Tango Therapeutics, Inc. 4

Director Lee Sung received RSU and stock option awards for Tango Therapeutics, Inc. common stock on June 5, 2026 as part of equity compensation.

On June 5, 2026, director Lee Sung of Tango Therapeutics, Inc. received two equity compensation grants: 570 shares of common stock in the form of restricted stock units (RSUs) that will vest in full on the earlier of June 5, 2027 or the next annual stockholders’ meeting, and a stock option to purchase 3,570 shares of common stock at an exercise price of $20.22 per share, vesting in 12 equal monthly installments beginning July 5, 2026, all subject to continued service. Following these awards, Lee Sung directly holds 22,870 shares of common stock, while the option award adds contingent rights to additional shares; the filing reflects routine director compensation rather than an open‑market purchase or sale. Because the RSUs were reported with a zero acquisition price, their value is inferred using the option exercise price as a proxy for the underlying share price at grant.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-262172

Alert Tier

5